TB-500 gets sold as shorthand for thymosin beta-4, and the research literature treats them as related but not identical: most of the actual data is on thymosin beta-4 itself, with direct TB-500 evidence being much thinner than the name recognition suggests.
What thymosin beta-4 and TB-500 are
Thymosin beta-4 is a naturally occurring protein involved in cell migration, wound healing, and tissue repair signaling. TB-500 is a synthetic peptide marketed as a stable fragment or analog of thymosin beta-4, sold specifically for research into the same repair pathways.
What's actually been studied
- Wound healing models. In multiple cutaneous (skin) wound models, thymosin beta-4 has been reported to accelerate wound closure compared to controls, with proposed mechanisms including improved cell migration, angiogenesis (new blood vessel formation), and reduced inflammation (scoping review, Applied Sciences (MDPI), 2025).
- Tissue distribution of the evidence. The most concentrated evidence base is in ocular (corneal) and skin/soft tissue wound settings, largely in animal and cell-culture models, not musculoskeletal tissue specifically.
- TB-500 specifically. A 2025 scoping review of the thymosin beta-4 and TB-500 literature reported that direct TB-500 evidence, as opposed to the broader thymosin beta-4 literature, was limited to a single included study (scoping review, Applied Sciences (MDPI), 2025).
Where the evidence is thin
This is worth being direct about: most of what gets cited to support TB-500 is actually thymosin beta-4 research, a related but distinct research question, and a recent scoping review of the combined literature found only one study directly evaluating TB-500 itself. The broader thymosin beta-4 evidence is also mostly preclinical, animal and cell-culture work, with limited human evidence, and what human evidence exists is concentrated in specific settings like corneal healing rather than the musculoskeletal tendon and ligament repair uses commonly discussed online.
The regulatory picture
Neither thymosin beta-4 nor TB-500 is FDA-approved for any human use. They're sold by research chemical vendors strictly for laboratory research, not for human use.
Papa's take
The gap between "thymosin beta-4 has real preclinical wound-healing data" and "TB-500 is a proven recovery peptide" is bigger than most discussion of this compound acknowledges. A scoping review finding a single direct TB-500 study is not a minor footnote, it's the headline finding, and it means most of what's repeated about TB-500 specifically is extrapolated from a related but different compound's animal data.
Sources
Sourcing for research
If you're sourcing TB-500 for laboratory research, purity documentation matters. See my vendor comparisons for how I evaluate third-party certificates of analysis.